Drug Profile
Research programme: Staphylococcus aureus monoclonal antibodies - Valneva/Merck
Alternative Names: S.aureus monoclonal antibodies - Intercell/MerckLatest Information Update: 27 Jun 2013
Price :
$50
*
At a glance
- Originator Intercell; Merck & Co
- Developer Intercell; Merck & Co; Valneva
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Staphylococcal infections
- Discontinued Streptococcal infections
Most Recent Events
- 27 Jun 2013 No development reported - Preclinical for Staphylococcal infections in Austria (Parenteral)
- 27 Jun 2013 No development reported - Preclinical for Staphylococcal infections in USA (Parenteral)
- 28 May 2013 Intercell has merged with Vivalis to form Valneva